NIKKEI 225
38,236.07 -38.03 (-0.10%) HANG SENG
18,489.48 +13.56 (+0.07%) CRUDE OIL
78.39 +0.28 (+0.36%) GOLD FUTURES
2,321.30 +12.70 (+0.55%) DOW
38,675.68 +449.98 (+1.18%) Bitcoin GBP
51,145.49 +698.82 (+1.39%)
ATOS May 2024 1.000 call
| Previous close | 0.6300 |
| Open | 0.6500 |
| Bid | 0.6500 |
| Ask | 0.8500 |
| Strike | 1.00 |
| Expiry date | 2024-05-17 |
| Day's range | 0.6500 - 0.7100 |
| Contract range | N/A |
| Volume | |
| Open interest | 512 |
GlobeNewswireAtossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Evaluate Synergy Between Antibody Drug Conjugates (ADCs) and (Z)-Endoxifen
SEATTLE, April 29, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced an expanded research agreement with Weill Cornell Medicine to explore the potential synergy between antibody drug conjugates (ADCs) and (Z)-endoxifen. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer. The expanded research agreement with Weill Cornel
- GlobeNewswire
Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer
SEATTLE, April 15, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) and Quantum Leap Healthcare Collaborative™ today announced the initiation of a new study to evaluate Atossa’s proprietary (Z)-endoxifen in combination with abemaciclib (VERZENIO®), a cyclin-dependent kinase (CDK) 4/6 inhibitor marketed by Eli Lilly and Company, in women with ER+/HER2- breast cancer. Atossa is a clinical stage biopharmaceutical company developing innovative medicines i
- GlobeNewswire
Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conference
SEATTLE, April 11, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced that Chief Executive Officer Steven Quay, M.D., Ph.D., will speak at the Noble Capital Markets Emerging Growth Healthcare Conference on Wednesday, April 17 at 9:00 am ET. The presentation will be available virtually and members of the Company’s leadership team will be available for one-on-one meetings with registered investors of the conference. Atossa is a clinical st
